In case you missed the webinar yesterday, the USCDI+ Cancer Registry data item list has been posted for public comment and is open for 60 days. You can see the links to the data item list below. As a reminder, the intention of these data item standards is to support early incidence reporting from EHRs and pathology labs.
- Here is a link to the recording and transcript: [https://nci.rev.vbrick.com/#/videos/5fbc7a0e-fe6f-46a2-aa5e-f0288ace48eb Click to follow link.">https://nci.rev.vbrick.com/#/videos/5fbc7a0e-fe6f-46a2-aa5e-f0288ace48eb]
- You may contact USCDI.Plus@hhs.gov with your questions.
- Here is a link to the Cancer Data Summit recordings: https://events.cancer.gov/nci/cancer-data-exchange-summit/agenda
- You can share your feedback on the USCDI+ Cancer Registry Data Elements at: https://uscdiplus.healthit.gov/uscdi
There will also be a listening session on August 29th at 2 pm ET, details forthcoming.
If you have any questions or comments about this initiative, please contact me directly at kknight@naaccr.org.
Karen
From: USCDI.Plus (OS/ONC) <USCDI.Plus@hhs.gov>
Sent: Tuesday, July 23, 2024 3:15 PM
Subject: Announcement: Public Comment Period for USCDI+ Cancer Registry Draft Data Element List
Public Comment Period Open for USCDI+ Cancer Registry Draft Data Element List
The Office of the National Coordinator for Health Information Technology (ONC) and the National Cancer Institute (NCI) are pleased to announce publication of the USCDI+ Cancer Registry draft data element list that is now available for public comment. We invite you to review and provide feedback on this important list.
About the USCDI+ Cancer Registry Draft Data Element List
This data element list is a crucial component of the Cancer Registry use case, which encompasses the Surveillance, Epidemiology, and End Results (SEER) program, the Centers for Disease Control and Prevention/National Program of Cancer Registries (CDC/NPCR) state cancer registries, and the North American Association of Central Cancer Registries (NAACCR). These entities are essential for understanding cancer incidence, treatment patterns, mortality, and survival in the US.
The objective of the USCDI+ Cancer use case is to enhance the efficiency and timeliness of cancer registry data collection by identifying standards (e.g., FHIR, mCODE) for efficient data extraction from Electronic Health Records (EHRs) and pathology labs. This data must be interoperable across cancer clinical, public health, and research communities.
Review and Comment
We encourage stakeholders to visit the USCDI+ platform to review the published data element list. Your feedback is invaluable in ensuring the quality and usability of cancer registry data. The comment period will be open for 60 days, providing ample time for thorough review and input.
How to Provide Feedback
- Visit the USCDI+ platform.
- Create an account.
- Review the published draft cancer registry data element list.
- Submit your comments and suggestions through the provided feedback form.
Upcoming Listening Session
In addition to the public comment period, we will be hosting a Cancer Registry Listening Session on August 29, 2024, from 2 – 3pm ET. This session will provide an opportunity to discuss the data element list, the collection process, and the impact on data sharing. Stay tuned for more details and registration information.
Contact Us
If you have any questions or need further information, please contact us at USCDI.Plus@hhs.gov.
Thank you for your participation and contribution to improving cancer registry data collection and interoperability.
We look forward to your valuable input!
USCDI+ Cancer Team